Literature DB >> 21041984

Influence of fatty liver on plasma small, dense LDL- cholesterol in subjects with and without metabolic syndrome.

Ikumi Sugino1, Koji Kuboki, Tomoko Matsumoto, Eiichi Murakami, Chiaki Nishimura, Gen Yoshino.   

Abstract

AIM: Small, dense low density lipoprotein (sLDL) is known as an atherogenic lipoprotein and is often associated with metabolic syndrome (MS). A high frequency of sLDL is found in hypertriglyceridemic subjects. Also, fatty liver (FL) is often associated with MS; therefore, we studied whether the association of FL increases sLDL- cholesterol (C) in subjects with MS.
METHODS: In total, 207 patients were enrolled in this study and FL was estimated by echogram. The presence of MS was diagnosed according to the Japanese Guidelines for the Definition of Metabolic Syndrome.
RESULTS: sLDL-C and sLDL-C/LDL-C in the MS group were higher than in the non-MS group. Also, sLDL-C and sLDL-C/LDL-C in the FL group were higher than in the non-FL group. The simple correlation coefficient (r) between plasma triglyceride and sLDL-C or sLDL-C/LDL-C in all subjects was 0.36 and 0.51. In the MS group, r values were 0.32 and 0.52 while, in the non-FL group, r was 0.32 and 0.38, respectively. Two-way ANOVA revealed that FL was a powerful determinant of plasma sLDL-C and sLDL-C/LDL-C, but MS was not. When we divided all subjects into four groups, i.e., MS(-)FL(-), MS(-)FL(+), MS(+)FL(-) and MS(+)FL(+), sLDL-C/LDL-C of MS(+)FL(+) was significantly higher than all other groups.
CONCLUSION: Association of MS and FL significantly increased sLDL-C and sLDL-C/LDL-C. The significant relationship between sLDL-C/LDL-C and plasma triglyceride in the FL group indicates that FL may produce triglyceriderich VLDL, a precurser of sLDL, thereby contributing to the appearance of sLDL particles in the plasma of MS patients with FL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21041984     DOI: 10.5551/jat.5447

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  14 in total

1.  Loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity.

Authors:  David E Stec; Darren M Gordon; Jennifer A Hipp; Stephen Hong; Zachary L Mitchell; Natalia R Franco; J Walker Robison; Christopher D Anderson; Donald F Stec; Terry D Hinds
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-09-04       Impact factor: 3.619

2.  Differing Associations between Fatty Liver and Dyslipidemia According to the Degree of Hepatic Steatosis in Korea.

Authors:  Ji Min Han; Hye In Kim; Yu-Ji Lee; Jung Won Lee; Kwang Min Kim; Ji Cheol Bae
Journal:  J Lipid Atheroscler       Date:  2019-09-21

3.  Fatty liver in men is associated with high serum levels of small, dense low-density lipoprotein cholesterol.

Authors:  Kaori Hosoyamada; Hirofumi Uto; Yasushi Imamura; Yasunari Hiramine; Eriko Toyokura; Yoshihiro Hidaka; Tomomi Kuwahara; Ken Kusano; Kazuto Saito; Makoto Oketani; Akio Ido; Hirohito Tsubouchi
Journal:  Diabetol Metab Syndr       Date:  2012-07-18       Impact factor: 3.320

4.  Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation.

Authors:  Klementina Fon Tacer; Damjana Rozman
Journal:  J Lipids       Date:  2011-07-02

5.  Hypertriglyceridemia is a major factor associated with elevated levels of small dense LDL cholesterol in patients with metabolic syndrome.

Authors:  Yonggeun Cho; Sang Guk Lee; Sun Ha Jee; Jeong Ho Kim
Journal:  Ann Lab Med       Date:  2015-11       Impact factor: 3.464

6.  Maternal obesity is associated with the formation of small dense LDL and hypoadiponectinemia in the third trimester.

Authors:  Barbara J Meyer; Frances M Stewart; Elizabeth A Brown; Josephine Cooney; Solveig Nilsson; Gunilla Olivecrona; Jane E Ramsay; Bruce A Griffin; Muriel J Caslake; Dilys J Freeman
Journal:  J Clin Endocrinol Metab       Date:  2013-01-21       Impact factor: 5.958

7.  Lepr(db/db) Mice with senescence marker protein-30 knockout (Lepr(db/db)Smp30(Y/-)) exhibit increases in small dense-LDL and severe fatty liver despite being fed a standard diet.

Authors:  Yoshitaka Kondo; Goji Hasegawa; Hiroshi Okada; Takafumi Senmaru; Michiaki Fukui; Naoto Nakamura; Morio Sawada; Jo Kitawaki; Takeshi Okanoue; Yuki Kishimoto; Akiko Amano; Naoki Maruyama; Hiroshi Obayashi; Akihito Ishigami
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

Review 8.  Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches.

Authors:  Dragana Nikolic; Niki Katsiki; Giuseppe Montalto; Esma R Isenovic; Dimitri P Mikhailidis; Manfredi Rizzo
Journal:  Nutrients       Date:  2013-03-18       Impact factor: 5.717

9.  Correlation between the small dense LDL level and nonalcoholic fatty liver disease: Possibility of a new biomarker.

Authors:  Ha Won Hwang; Jung Hwan Yu; Young-Joo Jin; Young Ju Suh; Jin-Woo Lee
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

Review 10.  Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.

Authors:  Anne Fougerat; Alexandra Montagner; Nicolas Loiseau; Hervé Guillou; Walter Wahli
Journal:  Cells       Date:  2020-07-08       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.